- Option for an exclusive worldwide license for potential
first-in class B7H3/PTK7 topo-I-payload bispecific antibody drug
conjugate (BsADC) program
- B7H3/PTK7 co-expression found in multiple solid tumor types,
including double-digit percent prevalence in lung, colorectal, and
head and neck cancers
- Rational combo opportunities with IDEAYA's DNA Damage Repair
(DDR) pipeline, including IDE161 (PARG)
- Targeting development candidate nomination in H2 2024
SOUTH
SAN FRANCISCO, Calif. and BEIJING,
China, July 31, 2024 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology
company committed to the discovery and development of targeted
therapeutics, announced that it has entered into an option and
license agreement for a potential first-in-class B7H3/PTK7
BsADC program with Biocytogen Pharmaceuticals
(Beijing) Co., Ltd. (Biocytogen,
HKEX: 02315), a global biotech company focusing on the discovery of
novel antibody/ADC therapeutics.
"The potential first-in-class B7H3/PTK7 topo-I-payload
BsADC program has the potential to be developed as a
monotherapy agent in multiple solid tumor types, and advances
IDEAYA's broader corporate strategy to enable wholly-owned
first-in-class rational combinations at the intersection of ADCs
and small molecule DDR-based therapies to deliver greater benefit
for patients," said Yujiro S. Hata, President and Chief
Executive Officer, IDEAYA Biosciences.
"We are thrilled to announce our collaboration with IDEAYA to
explore the promising combination of our potential first-in-class
ADC and IDEAYA's DDR small molecules," said Dr. Yuelei Shen,
President and CEO of Biocytogen. "This partnership leverages our
cutting-edge RenLite® platform and proprietary
linker-payload technology to enhance the precision and potency of
ADCs. IDEAYA's strong determination and rich experience in drug
development make us confident that this therapy could be rapidly
advanced to benefit patients."
The agreement grants IDEAYA an option for an exclusive worldwide
license from Biocytogen for a potential first-in-class B7H3/PTK7
topo-I-payload BsADC program. B7H3/PTK7 has been found to be
co-expressed in multiple solid tumor types, including double-digit
percent prevalence in lung, colorectal, and head and neck cancers,
among others.
Under the terms of the agreement, Biocytogen will receive an
upfront fee and upon an option exercise by IDEAYA, be entitled to
receive an option exercise fee, development and regulatory
milestones and commercial milestone payments, as well as
single-digit royalties on net sales. Total potential upfront,
option exercise and milestone payments equal an aggregate of
$406.5 million, including development
and regulatory milestones of $100.0
million.
Based on preclinical data, the potential first-in-class
B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program has the
potential to be developed as a monotherapy agent and used in
combination with multiple programs in IDEAYA's pipeline targeting
DDR-based therapies, including PARG inhibitor IDE161. A development
candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor
payload BsADC program is targeted for the second half of 2024.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
About Biocytogen
Biocytogen (HKEX: 02315) is a global
biotechnology company that drives the research and development of
novel antibody-based drugs with innovative technologies. Founded on
gene editing technology, Biocytogen leverages genetically
engineered
proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/
RenTCR-mimic™ ) platforms for fully human
monoclonal/bispecific/multispecific antibody discovery, bispecific
antibody-drug conjugate discovery, nanobody discovery and TCR-mimic
antibody discovery, and has established a sub-brand,
RenBiologics™, to explore global partnerships for an
off-the-shelf library of >400,000 fully human antibody sequences
against approximately 1000 targets for worldwide collaboration. As
of December 31, 2023, 103 therapeutic
antibody and multiple clinical asset
co-development/out-licensing/transfer agreements and 47
target-nominated RenMice® licensing projects have
been established around the globe, including several partnerships
with multinational pharmaceutical companies (MNCs). Biocytogen
pioneered the generation of drug target knock-in humanized models
for preclinical research, and currently provides a few thousand
off-the-shelf animal and cell models under the company's sub-brand,
BioMice™, along with preclinical pharmacology and
gene-editing services for clients worldwide. Headquartered in
Beijing, Biocytogen has branches
in China (Haimen Jiangsu,
Shanghai), USA (Boston,
San Francisco), and Germany (Heidelberg). For more information,
please visit http://en.biocytogen.com.cn.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i) the timing
of nomination of a development candidate, (ii) potential
development strategies, and (iii) the potential therapeutic
benefits of IDEAYA therapeutics. Such forward-looking statements
involve substantial risks and uncertainties that could cause
IDEAYA's preclinical and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including IDEAYA's
programs' early stage of development, the process of designing and
conducting preclinical and clinical trials, serious adverse events,
undesirable side effects or unexpected characteristics of drug
development candidates, the regulatory approval processes, the
timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property, and other
matters that could affect the sufficiency of existing cash to fund
operations. IDEAYA undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of IDEAYA in general, see IDEAYA's
current and future filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K filed on
February 20, 2024.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
Biocytogen Contacts
Antibody assets and platforms:
BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-option-and-license-agreement-for-potential-first-in-class-b7h3ptk7-topo-i-payload-bispecific-adc-program-with-biocytogen-302210790.html
SOURCE IDEAYA Biosciences, Inc.
